Exact Sciences Corporation
EXAS
Helyezés a részvények között
#1156
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Részvényárfolyam
$104.91
Utolsó szinkronizálás: 2026-03-23
Piaci kapitalizáció
$20.03B
Változás (1 nap)
0.00%
Változás (1 év)
67.24%
Ország
US
Kereskedés Exact Sciences Corporation (EXAS)
Kategória
Healthcare
Exact Sciences Corporation (EXAS) nyeresége
Nyereség ekkor: Dec 2025 TTM: $-203.89M
Exact Sciences Corporation legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi nyeresége $-203.89M. 2024 évben a vállalat $-1.04B nyereséget ért el, csökkenés a 2023 év nyereségéhez, amely $-201.75M volt. Az ezen az oldalon megjelenített nyereség a kamatok és adók előtti eredmény, azaz EBIT.
Exact Sciences Corporation nyereségtörténete 2000 és 2026 között
Nyereség az év végén
| Év | Nyereség | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $-203.89M | -3.83% |
| 2025 | $-212.01M | -79.54% |
| 2024 | $-1.04B | 413.60% |
| 2023 | $-201.75M | -68.11% |
| 2022 | $-632.57M | -24.92% |
| 2021 | $-842.51M | 1.62% |
| 2020 | $-829.06M | 103.98% |
| 2019 | $-406.44M | 132.18% |
| 2018 | $-175.06M | 52.78% |
| 2017 | $-114.58M | -31.47% |
| 2016 | $-167.21M | 5.96% |
| 2015 | $-157.80M | 57.73% |
| 2014 | $-100.05M | 115.09% |
| 2013 | $-46.51M | -11.27% |
| 2012 | $-52.42M | 82.81% |
| 2011 | $-28.68M | 148.14% |
| 2010 | $-11.56M | 26.60% |
| 2009 | $-9.13M | -6.29% |
| 2008 | $-9.74M | -18.55% |
| 2007 | $-11.96M | -7.40% |
| 2006 | $-12.92M | -11.05% |
| 2005 | $-14.52M | -21.61% |
| 2004 | $-18.52M | -34.64% |
| 2003 | $-28.34M | -5.16% |
| 2002 | $-29.88M | -99.87% |
| 2001 | $-23.49B | 176,087.09% |
| 2000 | $-13.33M | 0.00% |
Hasonló cégek vagy versenytársak nyeresége
| Vállalat | Nyereség | Nyereségkülönbség | Ország |
|---|---|---|---|
| $7.61B | -3,831.95% |
US
|
|
| $4.76B | -2,435.60% |
US
|
|
| $-252.70M | 23.94% |
US
|
|
| - | - |
CN
|
|
| $1.66B | -913.19% |
US
|
